PACS Group Inc. experienced a significant rally Tuesday, with shares climbing roughly 23% after the company reported first-quarter earnings that surpassed analyst expectations and unveiled an improved profit outlook for 2026. The stock reached an intraday high of $41.63 before settling near $39.30, with trading volume exceeding 2.1 million shares.
Strong Quarterly Performance
The post-acute care provider posted Q1 revenue of $1.42 billion, an 11.2% increase year-over-year, while net income jumped to $80.7 million from $28.4 million in the same period last year. Adjusted EBITDA surged 74.6% to $170.4 million. Earnings per share came in at $0.50, beating the FactSet consensus estimate by $0.10, and revenue topped the $1.36 billion forecast.
Key operational drivers included higher facility occupancy, which rose to 90.9% from 89.6%, and an improved skilled nursing mix, up 50 basis points. Same-store skilled nursing revenue advanced 8.0%. The company also benefited from a $23.3 million revenue boost from California's Workforce & Quality Incentive Program, with $16.3 million flowing through to adjusted EBITDA.
Guidance Upgrade and Buyback Authorization
Management raised its 2026 adjusted EBITDA target to a range of $605 million to $625 million, up from the prior forecast of $555 million to $575 million. Revenue guidance for 2026 was maintained at $5.65 billion to $5.75 billion, though it now excludes future acquisitions. CFO Carey Hendrickson attributed the upgrade to "excellent performance across both ramping and mature cohorts."
Additionally, the board authorized a $250 million share repurchase program, signaling confidence in the company's valuation. The buyback is flexible, with no set end date, and the board retains the right to modify or cancel it at any time.
Regulatory and Control Concerns Persist
Despite the upbeat news, PACS continues to face significant headwinds. The company disclosed that its disclosure controls remained ineffective as of March 31, with material weaknesses still unresolved. The 10-Q filing details ongoing investigations by the Department of Justice into Medicare issues, referral relationships, PDPM reimbursements, and COVID-era waiver policies, as well as a Securities and Exchange Commission probe covering accounting, reporting, and internal controls.
Management struck a cautious tone regarding the quality incentive payments, noting they are not included in guidance due to potential timing shifts between quarters, adding complexity for investors trying to isolate core operational gains.
Market Context and Peer Performance
The broader long-term care sector also saw gains, with Ensign Group rising about 4.0%, Pennant Group advancing 2.8%, and National HealthCare edging 0.4% higher. However, PACS stood out with the strongest company-specific catalyst. The company now operates 324 post-acute care facilities across 17 states, generating robust cash flow—net cash from operating activities reached $236.3 million, up from $150.2 million a year earlier.
With net leverage at just 0.1 times and available liquidity of approximately $800 million, including $250 million in cash, PACS appears well-positioned operationally. Yet the unresolved legal and control issues continue to cast a shadow, making Tuesday's rally a reflection of renewed investor confidence in the company's earnings power rather than a full endorsement of its risk profile.